Acceder

Threshold Pharmaceuticals, Inc (THLD): Opiniones

12,3K respuestas
Threshold Pharmaceuticals, Inc (THLD): Opiniones
2 suscriptores
Threshold Pharmaceuticals, Inc (THLD): Opiniones
Página
1.367 / 1.539
#10929

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

Era el unico valor que me quedaba en ING. Quería cerrar la cuenta.
Ahora toda mi artilleria está en http://www.activopro.es/ y http://www.activotrade.com/es/welcome.
Un saludo

#10930

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

me lo he perdido...sigo dentro pero esos 5,15 5,20 para saltar y si deja esa vela pincho moruno durante un año después de esa vela caídas.

veremos la hora que queda como la colocan.

me cago en mí ....

#10931

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

thld vendidas en 5.09

#10932

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

Bien jugado!.
Tienes pensado entrar en 4,3 o asi o ya la dejas por un tiempo?

#10933

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

La venta buena fue el otro día, se me escapo, y volver a entrar en 4.8. Ahora observar.

#10934

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

He encontrado esto por la web pero me falta el enlace para coraborarlo

$THLD Announces New Data on TH-302 to Be Presented at AACR-NCI-EORTC October 19 - 23, 2013

#10935

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

Asi es.

http://www.menafn.com/b54063c4-0c44-4a9d-98b2-7f9769fff45e/Threshold-Pharmaceuticals-Announces-New-Data-on-TH302-to-BePresented-at-AACRNCIEORTC?src=main

fase I y otra 1/2

nada, creo yo, que le haga tirar cohetes pero quizas un pequeño mete-saca si que pueda aprovecharse.
Estoy fuera del valor, vere mañana si se deja.

Por cierto, 4,71-4,72 umbral del bien y del mal diria ...

#10936

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

Threshold Pharmaceuticals Announces New Data on TH-302 to Be Presented at AACR-NCI-EORTC
Early Clinical Data on Combinations of TH-302 With Anti-Angiogenic Therapies in Solid Tumors; Preclinical Data on Combinations of TH-302 With Gemcitabine and Nab-Paclitaxel in Models of Pancreatic Cancer
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 10/07/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new data on its investigational hypoxia-targeted drug, TH-302, will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 19 - 23, 2013, in Boston, MA. The presentations will characterize early data from two ongoing clinical trials evaluating combinations of TH-302 with anti-angiogenic agents in solid tumors as well as preclinical data on the tolerability and activity of TH-302, gemcitabine, and nab-paclitaxel combinations in models of pancreatic cancer.

New data from a Phase 1 clinical trial combining TH-302 and pazopanib (Investigator Sponsored Trial 4001) in patients with advanced solid tumors will be presented in a poster session on Tuesday, October 22 (Abstract #C61). Updated data from a Phase 1/2 clinical trial combining TH-302 and sunitinib (Study 410) in patients with renal cell carcinoma, gastrointestinal tumors, or pancreatic neuroendocrine tumors will be presented in a poster session on Monday, October 21 (Abstract #B77). Emerging preclinical research suggests that anti-angiogenic therapy may increase tumor hypoxia. These two clinical trials further characterize the potential of combining TH-302 with anti-angiogenic agents.

In addition, results from preclinical research evaluating combinations of TH-302, gemcitabine, and nab-paclitaxel in xenograft models of pancreatic cancer will be presented in a poster session on Tuesday, October 22 (Abstract #C287).

Abstracts are now available on the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Online Proceedings and Itinerary Planner Web page, which can be accessed at http://www.abstractsonline.com/plan/start.aspx?mkey=%7B18FA2242%2DFD0D%2D4689%2D82A0%2DE4D68AC8A74A%7D.